Can you drink alcohol on Wegovy?

No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol — likely a secondary effect of GLP-1 on the brain reward system.

Does GLP-1 affect oral birth control?

Tirzepatide (Mounjaro, Zepbound) has documented reduced absorption of oral contraceptives during the first 4 weeks of each dose increase. Use backup contraception for ~4 weeks after starting + after each step-up. Semaglutide has no documented effect.

Can I take GLP-1 while pregnant?

No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life.

Is it safe to take GLP-1 long-term?

Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity.

What happens if I miss a weekly GLP-1 dose?

If within 5 days: take the missed dose as soon as you remember, then resume the regular schedule. More than 5 days late: skip it and inject your next scheduled dose. Never double up.

Can GLP-1 cause thyroid cancer?

The boxed warning is based on rodent studies showing medullary thyroid carcinoma (MTC) in mice and rats. No human cases have been attributed to GLP-1 use despite 10+ years post-approval surveillance.

ICD-10 · G47.33

Obstructive sleep apnea(OSA)

Obstructive sleep apnea (OSA) is a chronic condition in which breathing repeatedly stops and starts during sleep due to airway collapse. In December 2024 the FDA expanded Zepbound's indications to include moderate-to-severe OSA in adults with obesity — the first weight-loss drug approved for the condition.

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

OSA affects an estimated 39 million US adults. The repeated apneas during sleep cause oxygen desaturation, fragmented sleep, daytime fatigue, and over time increase cardiovascular risk. Excess weight is the single strongest modifiable risk factor — fat deposits around the upper airway worsen collapse during sleep. The SURMOUNT-OSA trial (NEJM, 2024) showed tirzepatide 10-15 mg weekly reduced apnea-hypopnea index by ~50% in adults with obesity, leading to the December 2024 FDA approval. CPAP therapy remains first-line for moderate-to-severe cases; weight-loss medication is typically adjunctive.

Symptoms

Loud snoring
Witnessed breathing pauses
Excessive daytime sleepiness
Morning headaches
Difficulty concentrating
High blood pressure

Risk factors

Obesity (BMI ≥30)
Male sex
Older age
Large neck circumference
Family history
Smoking
Alcohol use

Treatment options

CPAP therapy (gold standard)
Weight-loss interventions
Tirzepatide (Zepbound — FDA-approved for OSA in obesity)
Oral appliances
Upper airway surgery

GLP-1 evidence for obstructive sleep apnea

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Tirzepatide reduces apnea-hypopnea index by ~25-30 events/hour Source: NEJM, 2024 SURMOUNT-OSA 1 + 2 (n=469); FDA approved Zepbound for OSA on this evidence	AStrong evidence	SURMOUNT-OSA 1 + 2 (n=469); FDA approved Zepbound for OSA on this evidence
Weight loss mediates most of the OSA improvement SURMOUNT-OSA pre-specified mediation analysis showed AHI reduction tracks with weight loss	AStrong evidence	SURMOUNT-OSA pre-specified mediation analysis showed AHI reduction tracks with weight loss
Tirzepatide can replace CPAP for most moderate OSA cases No head-to-head data; SURMOUNT-OSA was adjunctive to CPAP-eligible patients	DPreliminary	No head-to-head data; SURMOUNT-OSA was adjunctive to CPAP-eligible patients
Semaglutide also improves OSA outcomes Class-level mechanism plausible; trials underway, no FDA-approved indication for Wegovy	CLimited evidence	Class-level mechanism plausible; trials underway, no FDA-approved indication for Wegovy

Related GLP-1 medications

Mounjaro

GIP/GLP-1 dual receptor agonist · ~$1023.04/mo

View details

Zepbound

GIP/GLP-1 dual receptor agonist · ~$1059.87/mo